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BACKGROUND: We used bleomycin, etoposide, cisplatin (BEP), the most effective regimen in the treatment of germ cell tumours
(GCTs) and increased dose-density by using pegfilgrastim to shorten cycle length. Our aim was to assess safety and tolerability.
METHODS: Sixteen male patients with intermediate or poor prognosis metastatic GCT were treated with four cycles of 3-day BEP with
G-CSF on a 14-day cycle for a planned relative dose-density of 1.5 compared with standard BEP.
RESULTS: Eleven intermediate and five poor prognosis patients were treated. In all, 14 of 16 patients completed the study treatment.
Toxicities were comparable to previous studies using standard BEP, except for mucositis and haematological toxicity that were more
severe. The overall relative dose-density for all 16 patients was mean 1.38 (range 0.72–1.5; median 1.46). Complete response was
achieved after chemotherapy alone in two patients (13%) and following chemotherapy plus surgery in nine additional patients (56%).
Four patients (25%) had a partial response and normalised their marker levels. At a median follow-up of 4.4 years (range 2.1–6.8) the
estimated 5-year progression-free survival probability is 81% (95% CI 64–100%).
CONCLUSION: Accelerated BEP is tolerable without major additional toxicity. A randomised controlled trial will be required to obtain
comparative efficacy data.
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Patients with metastatic germ cell tumours (GCTs) have been
classified into three prognostic groups (International Germ Cell
Cancer Collaborative Group (IGCCCG), 1997). Despite excellent
outcomes in good prognosis patients, 5-year progression-free
survival (PFS) rates in intermediate and poor risk patients remain
unsatisfactory at 75% and 41%, respectively (International Germ
Cell Cancer Collaborative Group (IGCCCG), 1997). For poor
prognosis patients treated with bleomycin, etoposide, cisplatin
(BEP) in clinical trials, 5-year PFS rates of 44 and 41% were
recently confirmed (Motzer et al, 2007; Daugaard et al, 2010).
Studies initiated before the introduction of the IGCCCG
prognostic groups in 1997, included a mixture of intermediate
and poor prognosis patients by those criteria (Collette et al, 1999;
Hinton et al, 2003). There have been four main approaches aimed
at improving on the results of BEP as first-line therapy for these
patients:
(1) Intensification of cisplatin dose.
(2) Use of new drugs.
(3) Sequential alternating drug combinations.
(4) Increased drug doses using growth factor or stem cell support.
Over the last 20 years, none of these approaches has been shown
to improve outcomes and most have increased toxicity (Nichols
et al, 1991, 1998; de Wit et al, 1998; Kaye et al, 1998; Hinton et al,
2003). The only exception is the recent publication of an abstract
showing a 12% improvement in 3-year PFS for intermediate
prognosis patients treated with paclitaxel-BEP (T-BEP) (de Wit
et al, 2011). This may be the first improvement in outcome since
the development of BEP 25 years ago (Williams et al, 1987) and full
publication is awaited.
Higher drug doses can be given with growth factor support.
Increased doses of cisplatin and etoposide (Daugaard and Rørth,
1986) and ifosphamide and etoposide (Schmoll et al, 2003) have
been achieved but toxicity was unacceptable. Subsequently stem
cell support was used to deliver high-dose VIP with a cycle interval
of 21 days: over 5 days, the dose of etoposide was escalated four-
fold (1500 mg m – 2), that of ifosphamide was doubled (12 g m – 2)
and cisplatin was given in standard dose (100 mg m – 2). The
regimen was more toxic and no more effective than BEP in a
randomised study of 137 patients (Daugaard et al, 2010).
High-dose therapy as first-line management has been tested in a
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clinical trial of 219 patients: four cycles of BEP were compared with
two cycles followed by two high-dose procedures each with
stem cell autograft. There was no improvement in 1-year
durable complete response (CR) rate compared with BEP (Motzer
et al, 2007).
By contrast, dose-dense regimens increase dose-exposure by
shortening inter-treatment intervals rather than by increasing
doses. It has been hypothesised that delivering the same total drug
dose in the same number of cycles but in a shorter time should
improve the impact of therapy (Citron et al, 2003; Fornier and
Norton, 2005). Studies in a variety of tumours have shown that
relapse-free and overall survival can be improved but the results
are inconsistent (Fizazi and Zelek, 2000; Thatcher et al, 2000;
Ardizzoni et al, 2002; Citron et al, 2003; Pfreundschuh et al, 2004;
Lorigan et al, 2005; Bonilla et al, 2010).
We planned to increase the dose-density of BEP, the most
effective regimen in the treatment of GCTs, by using pegfilgrastim
to shorten the cycle length. This is a novel approach in GCTs and
our primary aim was to assess safety and tolerability.
PATIENTS AND METHODS
Patients
Ethical approval was granted by the UK’s Eastern Multi-Centre
Research Ethics Committee (EudraCT number: 2004–000847 –79,
ISRCTN18505589) and all patients gave written informed consent.
Patients were eligible for this study if they had metastatic GCT with
either intermediate or poor prognosis disease (International Germ
Cell Cancer Collaborative Group (IGCCCG), 1997). Histological
confirmation of GCT was desirable but not essential providing
a-foetoprotein41000 ng ml – 1 and/or b-human chorionic gonado-
trophin (b-HCG) 45000 IU l – 1.
Male patients with no history of previous malignancy (except
basal cell carcinoma of the skin) nor prior treatment with
chemotherapy or radiotherapy were eligible. No induction
treatment was permitted before BEP. Patients were excluded if
creatinine clearance was below 60 ml min – 1 (unless secondary to
obstructive uropathy, which could be relieved by nephrostomy) or
if neutrophils o1.0 109 l – 1 and platelets o100 109 l – 1 before
the start of treatment.
Patients were staged with CT scan of brain, chest, abdomen and
pelvis. Bone scan was undertaken if clinically indicated by
symptoms or elevated alkaline phosphatase. Audiometry, lung
function tests and EDTA clearance were undertaken before, and on
completion of treatment. Neurotoxicity was assessed by clinical
examination and using a structured patient questionnaire at
baseline and at intervals thereafter (Cassidy et al, 1998).
Treatment
The protocol was based on a 3-day version of BEP, which delivers
the same total drug doses as standard BEP (de Wit et al, 2001;
Fossa et al, 2003). The accelerated BEP regimen consisted of four
cycles of 3-day BEP with an intended cycle interval of 14 days.
Cisplatin 50 mg m – 2 i.v. was administered on days 1 and 2 and
etoposide 165 mg m – 2 i.v. on days 1, 2 and 3. Bleomycin infusions
(30 000 units) were administered on day 2 and between days 6– 8
and 10–12. Pegfilgrastim (Neulasta) 6 mg was given subcuta-
neously on day 4 of each cycle. The planned elapsed time was
therefore 8 weeks rather than 12 weeks for a planned relative dose-
density of 1.5 for each drug compared with standard BEP.
Subsequent cycles of chemotherapy were scheduled to com-
mence on day 15 and were given if the neutrophil count was
X1.0 109 l – 1 and the platelet count was X50 109 l – 1. If these
levels were not achieved, counts were repeated at 24-h intervals
until the criteria were met. If there were grade 3 or 4 mucosal
toxicity, diarrhoea or skin toxicity, then chemotherapy was
delayed until recovery. Patients with a delay of a week or longer
were withdrawn from the study and completed treatment with the
standard (3-weekly) BEP regimen.
Serious adverse event reporting and stopping rules
Toxicity severity was reported according to the Common
Terminology Criteria for Adverse Events (CTCAE) v3.0 (Cancer
Therapy Evaluation Program, 2006). The following were specified
as serious adverse events (SAEs) in this trial and also comprised
part of the stopping rules:
 Life-threatening bleeding refractory to platelet support.
 Life-threatening sepsis with septic shock.
 Impairment of renal function with a reduction in clearance
below 60 ml min – 1.
 Death on treatment from any cause.
 Fatal bleomycin pulmonary toxicity.
An incidence of these specified events of 415% would have
been considered unacceptable. Patients were entered in cohorts
of 5, 5 and 6 and toxicity was assessed by an independent data
monitoring committee. Trial entry was suspended between each
cohort until each patient had completed planned chemotherapy
and post-treatment assessment (9–10 weeks after entry).
Bleomycin toxicity
Close clinical monitoring was used to assist in weighing the risks
and benefits of each dose of bleomycin for the individual patient
(Saxman et al, 1997; Nichols et al, 1998; O’Sullivan et al, 2003).
Patients were questioned regarding respiratory symptoms and
examined for basal crepitations before each dose of bleomycin.
Chest radiographs were serially reviewed every 15 days immedi-
ately before each cycle to detect abnormalities suggestive of an
interstitial process (Saxman et al, 1997).
Response evaluation
Response was assessed in all patients within 3 to 4 weeks of the
start of the final cycle of therapy (i.e., weeks 9 to 10 of the study)
with CT scan of chest, abdomen and pelvis and repeat of any other
investigation abnormal at the outset. In addition, standard blood
tests (including tumour markers), Cr51-EDTA clearance, audio-
metry, pulmonary vital capacity, neurotoxicity questionnaire and
clinical assessment were performed.
Patients with residual masses (abdominal or pulmonary lesions
41 cm) post-treatment were considered for surgical resection
within 6– 8 weeks. If markers were still decreasing, continued
observation was considered appropriate. If there was a significant
rise in markers (doubling or two consecutive rises), the patient was
defined as a treatment failure eligible for salvage chemotherapy at
the investigator’s discretion.
After completion of treatment, patients were followed up
according to institutional practice. CT of chest, abdomen and
pelvis was performed 2 years after completion of treatment.
Disease progression was defined as a consistent increase in tumour
markers (at least two measurements 1 –2 weeks apart) or clinical
or radiological evidence of an increase in the size of residual
lesions or occurrence of new lesions.
Statistical design
This study was a multi-centre, non-randomised, non-controlled
phase I study. The primary objectives were to determine the
feasibility of the regimen and to determine toxicity particularly
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with respect to renal, pulmonary and neurological function. The
secondary objectives were to estimate the response rate and PFS
using a Kaplan– Meir estimator.
To assess drug delivery, we calculated dose-density for each
drug as the product of two quantities: the ratio of days taken by the
existing BEP regimen to days taken by the accelerated regimen;
and the proportion of planned doses given. We set no study target
and a patient who completed the accelerated regimen within the
planned time and received all planned doses had a dose-density of
1.5. As bleomycin may be discontinued prematurely to minimise
the risk of toxicity in 5–30% of patients receiving standard BEP
(Saxman et al, 1997; Nichols et al, 1998), patients who stopped
bleomycin early had their dose-density calculated at the day of
final dose.
RESULTS
Patients
Between August 2004 and February 2009, 16 patients (11 with
intermediate prognosis and 5 with poor prognosis) non-seminoma
GCT were recruited from four UK centres. The median age of the
cohort was 29 years (range 20–41). The baseline characteristics of
the patients and their response to therapy are shown Table 1.
There were no treatment related deaths.
Dose-density of regimen
A total of 14 of 16 patients completed all four planned cycles within
the trial. In all, 12 of these 14 (75% of all patients) completed the
accelerated regimen with full doses of all three drugs (Table 2). The
remaining two patients received full doses of cisplatin and
etoposide, but with early cessation of bleomycin (see below).
Overall 13 out of 16 (81%) patients commenced the fourth cycle
within 1 week of schedule, and 12 of these completed their cisplatin
and etoposide with total delays of no more than 5 days. Relative
dose-density for all 16 patients was cisplatin 1.37 (range 0.49–1.5),
etoposide 1.37 (0.5–1.5) and bleomycin 1.40 (0.98– 1.5) for an
overall relative dose-density of 1.38 (range 0.72–1.5; median 1.46).
Withdrawal from study
Two patients were withdrawn from the study after cycle 2 because
of toxicity. Both completed chemotherapy using 3-weekly cycles.
They remain alive and progression-free and are included in the
response analysis.
Patient 002 was admitted on day 7 of cycle one with grade 2
mucositis, grade 3 neutropaenic sepsis and grade 4 thrombocyto-
paenia. In cycle 2, the same toxicity occurred again and he was
withdrawn from the study. He received a further cycle of BEP (after
an interval of 24 days, rather than the planned 14 days). Bleomycin
was stopped electively because of patient frailty (no pulmonary
toxicity was reported) and he received a final cycle of EP. Both
these cycles were again complicated by neutropaenic sepsis. He
was a complete responder to chemotherapy and surgery.
Patient 007 was withdrawn from the study after admission on
day 12 of cycle 2 with grade 3 mucositis and grade 4 neutropaenia
and thrombocytopaenia. During this episode he missed a single
dose of bleomycin. He subsequently received two cycles of
standard 3-weekly BEP. No pulmonary toxicity was reported. He
was a complete responder to chemotherapy and surgery.
Haematological toxicity
Table 3 shows the highest toxicity score recorded during the study
chemotherapy for each patient. Overall there were 27 SAEs
reported, including nine reports of admission for neutropaenic
sepsis and two for the management of thrombocytopaenia. The
percentage of patients with grade 3/4 haematological toxicity
recorded during at least one cycle was: thrombocytopaenia 56%,
neutropaenia 63% and febrile neutropaenia 38%. Four patients
received platelet support and nine received red cell transfusions.
Renal toxicity
Four patients had grade 1 toxicity and one grade 2 toxicity
(Table 3). EDTA clearance was available at baseline and 8 weeks
for 12 out of 14 patients who completed the protocol. Mean renal
function at baseline was 130 ml min – 1 (range 88– 208) and at 9– 10
weeks the mean was 84 ml min – 1 (range 56– 136) a mean reduction
to 66% of baseline (range 50– 89%).
Table 1 Patient baseline characteristics and response to therapy
Trial
no.
Age
(at enrolment)
Prognostic category
(IGCCCG classification)
Response to
chemotherapy Surgery
Surgical
histology
Overall
response Relapse Comment
001 41 Poor Progression None Progression Progression
002 20 Poor PR marker neg RPLND No viable tumour CR chemo and surgery Withdrawn
003 21 Intermediate PR marker neg RPLND No viable tumour CR chemo and surgery
004 22 Intermediate PR marker neg RPLND No viable tumour CR chemo and surgery
005 30 Intermediate PR marker neg None PR marker neg Relapse
006 37 Poor PR marker neg RPLND No viable tumour CR chemo and surgery
007 35 Intermediate PR marker neg Node biopsy No viable tumour PR marker neg Withdrawn
008 23 Intermediate PR marker neg RPLND No viable tumour CR chemo and surgery
009 29 Intermediate PR marker neg None PR marker neg
010 29 Intermediate PR marker neg RPLND Foci of viable tumour
(sarcomatoid change)
PR marker neg Relapse Died tumour
011 26 Intermediate PR marker neg RPLND No viable tumour CR chemo and surgery
012 21 Intermediate Complete remission None CR chemotherapy alone
013 33 Poor PR marker neg Orchidectomy No viable tumour CR chemo and surgery
014 29 Poor PR marker neg RPLND No viable tumour CR chemo and surgery
015 33 Intermediate PR marker neg RPLND No viable tumour CR chemo and surgery
016 28 Intermediate Complete remission None CR chemotherapy alone
Abbreviations: CR¼ complete response; neg¼ negative; PR¼ partial response; RPLND¼ retroperitoneal lymph node dissection. Salvage therapy: patient 001: Granulocyte
colony stimulating factor (GCSF), actinomycin D, methotrexate, etoposide, cisplatin (GAMEC) chemotherapy (Shamash et al, 2007b) followed by RPLND showing no viable
tumour. Remains progression free 6 years later. Patient 005: GAMEC chemotherapy (Shamash et al, 2007b) followed by RPLND showing no viable tumour. Relapsed in
abdomen. Response to irinotecan, paclitaxel, oxaliplatin (IPO) chemotherapy (Shamash et al, 2007a); followed by high-dose thiotepa, topotecan, carboplatin with stem cell
reinfusion (Shamash et al, 2007a). Radiotherapy to para-aortic nodes. Remains progression free 4 years later. Patient 010: RPLND and orchidectomy included small foci of
immature teratoma with sarcomatoid change. Progression of lung metastases 3 months later. VIDE chemotherapy (Ladenstein et al, 2010) – progressed. Response to IPO
(Shamash et al, 2007a); followed by high dose thiotepa, topotecan, carboplatin with stem cell reinfusion (Shamash et al, 2007a). Progressed after 9 months. Died of disease.
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Pulmonary toxicity
Table 3 shows that grade 3/4 pulmonary symptoms were reported
for a single patient who had disease related dyspnoea (grade 3),
hypoxia (grade 2) and cough (grade 1). These symptoms all
improved towards the end of chemotherapy and he received full
dose bleomycin.
Table 2 shows that bleomycin was delivered within 7 days of
schedule and in full dose to 12 out of 16 patients. Two patients
were withdrawn from the study because of non-pulmonary toxicity
(see above). One patient missed the final dose of bleomycin and
was recorded as having a cough but no dyspnoea or other
abnormalities. He made a full recovery. One patient received only
180 000 units of bleomycin (six doses) because of grade 1 cough
and grade 1 dyspnoea. He made a full recovery.
Lung function data were available on eight patients. At baseline
the mean lung diffusing capacity for carbon monoxide (DLCO) was
93% of predicted (range 60– 119%). At the completion of
treatment, this showed a reduction to a mean of 66% of expected
(range 45– 79%). This reduction in DLCO affected all patients and
there was a mean reduction to 73% of the baseline value (range
57–83%). Five patients had long-term follow-up data and all
showed improvement.
Neurological toxicity
Table 3 shows that 10 patients had no recorded neurotoxicity.
Neurological assessment was reported at 8 weeks on 12 patients of
whom 4 were normal and 6 had objective evidence of a grade 1
sensory deficit: this recovered in all but a single patient who had
grade 2 signs at 10 months. Two patients had grade 2 sensory loss
(one with grade 2 motor signs in the hands): both recovered on
later assessments.
Patient questionnaires were returned for the 8-week assessment
on 11 patients of whom 4 had symptoms all of which improved on
follow-up so that only 1 patient still had troubling symptoms at
most recent follow-up.
Auditory toxicity
Three of 14 patients had grade 2 auditory toxicity, defined as
hearing loss not requiring intervention (Table 3). Mild tinnitus not
interfering with the activities of daily living (grade 2) was reported
by four patients. Pre- and post-treatment audiograms were
available on 11 patients of whom 6 showed no change. Five
showed substantial high-tone loss at 8 Hz with a threshold of
40–70 dB. Of the three cases with longer follow-up, two showed
full recovery on audiograms at 1 and 3 years. Thus, 8 out of
11 (72%) had objectively normal hearing in the long term.
Other toxicity
Mucositis was common with 50% of patients experiencing grade 2
symptoms and 25% experiencing grade 3 symptoms during at least
one cycle of their treatment (Table 1). Three patients had
transitory grade 3 dysphagia. Two patients were treated for
hypomagnesaemia.
Response analysis
All 16 patients were included in the response analysis (see Table 1).
The overall objective response rate was 94%. Complete response
Table 2 Drug delivery and dose-density
Bleomycin Etoposide Cisplatin Overall
Delivered
total drug
dose (IU)
Overall
time
(days to
final dose)
Relative
dose-
density
Delivered
total
drug dose
mgm–2
Overall
time
(days to
final dose)
Relative
dose-
density
Delivered
total
drug dose
mgm–2
Overall
time (days
to final
dose)
Relative
dose-
density
Days to
start
cycle 4
Mean
relative
dose-
density
Trial
no.
Target dose
and time 360000 52–54 1.50 2000 44 1.50 400 43 1.50 42 1.50
001 360 000 52 1.50 2000 44 1.50 400 43 1.50 42 1.50
002 240 000 46 1.17 2000 132 0.50 400 131 0.49 130 0.72
003 360 000 53 1.50 2000 44 1.50 400 43 1.50 42 1.50
004 360 000 52 1.50 2000 44 1.50 400 43 1.50 42 1.50
005 360 000 52 1.50 2000 44 1.50 400 43 1.50 42 1.50
006 360 000 52 1.50 2000 44 1.50 400 43 1.50 42 1.50
007 330 000 76 0.98 2000 64 1.03 400 63 1.02 62 1.01
008 360 000 53 1.50 2000 45 1.47 400 44 1.47 43 1.48
009 360 000 58 1.40 2000 51 1.29 400 50 1.29 49 1.33
010 360 000 55 1.47 2000 48 1.38 400 47 1.37 46 1.41
011 360 000 61 1.33 2000 44 1.50 400 43 1.50 42 1.44
012 360 000 54 1.50 2000 44 1.50 400 43 1.50 42 1.50
013 330 000 55 1.35 2000 49 1.35 400 48 1.34 47 1.35
014 180 000 30 1.35 2000 44 1.50 400 43 1.50 42 1.45
015 360 000 60 1.35 2000 52 1.27 400 51 1.26 50 1.29
016 360 000 53 1.50 2000 44 1.50 400 43 1.50 42 1.50
All patients
Mean 337 500 53.9 1.40 2000 51.8 1.37 400 50.8 1.37 49.8 1.38
Range (180– 360) (30 – 76) (0.98 – 1.5) (2000–2000) (44 – 132) (0.5 – 1.5) (400 – 400) (43 – 131) (0.49 – 1.5) (42 – 130) (0.72 – 1.5)
Excluding
002, 007
Mean 345 000 52.9 1.45 2000 45.8 1.45 400 44.8 1.45 43.8 1.45
Range (180– 360) (30 – 61) (1.33 – 1.5) (2000–2000) (44 – 52) (1.27 – 1.5) (400 – 400) (43 – 51) (1.26 – 1.5) (42 – 50) (1.29 – 1.5)
Notes on bleomycin dosage. Patient 002: patient withdrawn. Bleomycin discontinued electively. No record of pulmonary symptoms or toxicity. Patient 007: patient withdrawn.
One dose of bleomycin omitted. No record of pulmonary symptoms or toxicity. Patient 013: pulmonary symptoms. Bleomycin stopped. Full recovery (see text). Patient 014:
pulmonary symptoms. Bleomycin stopped. Full recovery (see text).
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with normal radiology and tumour markers was achieved in 11 out
of 16 patients (69%) – after chemotherapy alone in 2 patients
(13%) and following surgery in 9 patients (56%). As no viable
cancer cells were detected in any of these specimens, these patients
were all classified as complete responders. A further four patients
(25%) had a partial response (PR) and normalised their marker
levels. This included one patient with small foci of immature
teratoma with sarcomatoid change. He also had residual lung
metastases that progressed (see Table 1). One patient was classified
as a treatment failure because of increasing tumour markers within
7 weeks of completion of accelerated BEP, having never normal-
ised his b-HCG levels. Salvage treatment was at the investigator’s
discretion and is summarised in Table 1.
Progression-free survival
Median follow-up was 4.4 years (range 2.1–6.8). Three patients
have experienced progression since treatment and one of these has
died because of progressive disease (see Table 1). Figure 1 shows
that the estimated 5-year PFS probability is 81% (95% CI
64–100%) (panel A). The estimated 5-year overall survival
probability is 92% (95% CI 77– 100%) (panel B).
DISCUSSION
This phase I study showed that accelerated BEP does not produce
significant additional toxicity, compared with the standard
3-weekly regimen, particularly with respect to renal function and
pulmonary toxicity. Accelerated BEP causes more mucositis than
standard BEP with 50% of patients having grade 2 toxicity on at
least one occasion and 25% grade 3. This contributed to the
withdrawal of two patients from the study treatment. The
haematological toxicity was similar to that reported with VIP,
BOP/VIP-B and CBOP/BEP (Kaye et al 1998; Nichols et al, 1998;
de Wit et al 2001; Christian et al 2003; Fossa et al, 2005) but greater
than that reported with 3-weekly BEP (de Wit et al 2001), even
when used to treat intermediate and high-risk patients (Kaye et al
1998; Nichols et al 1998).
Standard BEP delivering cisplatin 400 mg m – 2 causes renal
injury with a reduction to 77–89% of the baseline clearance
measurement (Macleod et al 1988; Hamilton et al 1989; Bissett
et al, 1990). Previous studies that increased the dose-density or
dose-intensity of cisplatin caused increased nephrotoxicity: double
dose cisplatin reduced renal function to 68% of baseline (Daugaard
and Rørth, 1986); CBOP/BEP caused a mean reduction of EDTA
clearance to 61 and 70% of baseline in two studies (Horwich et al,
1989, 1994). Accelerated BEP in our study reduced mean renal
function to 66% of baseline. This toxicity is greater than that of
standard BEP, but is comparable to that of other intensive
regimens and is not dose-limiting.
Bleomycin pulmonary toxicity was a major concern in the
planning phase of this study. The administration of standard BEP
involves the delivery of bleomycin 360 000 units in 12, weekly
intravenous doses of 30 000 units: the landmark study that
established BEP as the standard of care reported fatal bleomycin
toxicity in 2% of cases (Williams et al, 1987). Increased dose-
density of bleomycin has been explored in the development
of CBOP/BEP. The original version of this regimen delivered
360 000 units over 4 weeks and a total dose of 450 000 units.
This was associated with fatal toxicity in 3 of 15 patients
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Figure 1 Kaplan–Meier survival curve with upper and lower 95%
confidence bands (dashed). The estimated 5-year PFS probability is 81%
(95% CI 64–100%) (A). The estimated 5-year overall survival probability is
92% (95% CI 77–100%) (B).
Table 3 Highest toxicity scores for each patient during chemotherapy
Grade 0 1 2 3 4
Haematological
Platelets 5 1 1 5 4
Neutropaenia 4 2 0 3 7
Febrile neutropaenia 9 1 0 6 0
Transfusion
Platelets 12 4
Red cells 7 9
Pulmonary
Cough 6 10
Dyspnoea 10 3 2 1
Hypoxia 13 0 3
Pulmonary infiltrates 16
Renal
Creatinine 11 4 1
Gastrointestinal
Nausea 0 10 4 2
Vomiting 2 4 10
Diarrhoea 13 1 1 1
Constipation 8 7 1
Mucositis 2 2 8 4
Dysphagia 11 2 0 3
Skin rash 8 4 2 1 1
Neuropathy
Sensory 10 4 2
Muscle weakness 14 1 1
Hearing 8 5 3
Other
Fatigue 1 6 7 2
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(Horwich et al, 1989). The current CBOP/BEP regimen delivers
180 000 units over 4 weeks in the induction protocol with a further
11-weekly doses of bleomycin 15 000 units to a total dose of
345 000 units with acceptable pulmonary toxicity (Christian et al,
2003; Fossa et al, 2005). The accelerated BEP protocol replicates
the bleomycin dose-density of the induction protocol but
continues it for 8 weeks (to a total dose of 360 000 units). We
found that the increased mean dose-density of bleomycin of 1.40
(range 0.98– 1.5; median 1.49) relative to standard BEP was
tolerable. The reduction in DLCO was consistent with previous
studies and as expected showed improvement on follow-up
(Osanto et al, 1992). Bleomycin was discontinued in two patients
after 180 000 and 330 000 units because of symptoms suggestive of
toxicity but both made a full recovery. Previous studies have
reported premature discontinuation of bleomycin to minimise the
risk of toxicity in 5–30% of patients receiving standard BEP
(Saxman et al, 1997; Nichols et al, 1998). The reported incidence of
bleomycin toxicity is 3–5% with a death rate of 1–2% (Williams
et al, 1987; Kaye et al, 1998; Nichols et al, 1998; O’Sullivan et al
2003). Our results are consistent with previous findings but the
study is too small to exclude an increased risk.
We used a 3-day version of BEP, which delivers the same total
drug doses as standard BEP (de Wit et al, 2001; Fossa et al, 2003),
but in 8 weeks, rather than 12. The 3-day regimen has only been
assessed previously in good prognosis patients, where it was as
effective as 5-day BEP, when given at 3-weekly intervals (de Wit
et al, 2001), but caused increased tinnitus and gastrointestinal
toxicity over four cycles (Fossa et al, 2003). The 3-day regimen was
chosen to permit the administration of Pegfilgrastim (Neulasta)
6 mg on day 4 and to allow an 11 day interval without
myelosuppressive drugs.
While our study was being conducted an Australian study of
accelerated BEP using a 5-day BEP schedule given every 2 weeks
was opened for patients in all prognostic groups (Grimison et al,
2011). Bleomycin was administered at weekly intervals and
therefore continued after administration of the other drugs had
been completed. An interim report states that toxicity was
acceptable with 36 out of 41 (88%) patients eligible to start a
fourth cycle of treatment within 1 week of schedule (Grimison
et al, 2011); in our study this was 13 out of 16 patients (81%). They
report that 1-year PFS was 80% for 25 patients with an
intermediate or poor prognosis (Grimison et al, 2011). Our study
with a group of 16 patients of a similarly mixed prognosis showed
an estimated 5-year PFS probability of 81% (95% CI 64– 100%). As
the data from both studies mature, combined analysis may give a
better estimate of efficacy to assist in considering the case for a
randomised trial.
CONCLUSION
Accelerated BEP is a novel, dose-dense regimen that was tolerable
for the majority of our patients. It shares with T-BEP (de Wit et al,
2011) the simple concept of intensifying standard BEP. Mucositis
and haematological toxicity were somewhat increased. Renal
toxicity was comparable to that of other intensive regimens.
Neurological and auditory toxicity were acceptable. The sample
size was too small to exclude a change in the incidence of
bleomycin pulmonary toxicity, which is a rare event. We conclude
that accelerated BEP merits further evaluation in terms of efficacy:
this would require a multinational randomised controlled trial.
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